Skip to main content
What can we learn from longitudinal peripheral blood multi-omic profiling in at-risk individuals?

50 RA converters vs.

Aurelie Najm AurelieRheumo

9 months 1 week ago
What can we learn from longitudinal peripheral blood multi-omic profiling in at-risk individuals? 50 RA converters vs. non converters from StopRA study Decision tree showing highest risk for conversion to clinical RA in Individuals w/ -CCP3 ≥108 units -T peripheral helpers https://t.co/jw53EB6tI6
#0774
Multi-omic profiling of anti-CCP3+ “at-risk” individuals reveals Tph & cytotoxic CD8+ expansions, altered

Mrinalini Dey DrMiniDey

9 months 1 week ago
#0774 Multi-omic profiling of anti-CCP3+ “at-risk” individuals reveals Tph & cytotoxic CD8+ expansions, altered gene/chromatin profiles and predictive model (AUC 0.77) for RA conversion PTPN22 locus accessibility & Tph ≥ 2.45% identify highest risk. @RheumNow #ACR25 https://t.co/JDSMkdmoGv
Not just for salivary glands—lacrimal ultrasound helps too.

In early Sjögren’s, lacrimal + salivary US clearly dis

Jiha Lee JihaRheum

9 months 1 week ago
Not just for salivary glands—lacrimal ultrasound helps too. In early Sjögren’s, lacrimal + salivary US clearly distinguished SjD from sicca (AUC up to 0.97). Noninvasive, reproducible, and highly diagnostic. @RheumNow #ACR25 Abstract #0507
A new marker for stratification of ILD in dermatomyositis: Anti MDA5 antibodies!

Japanese study
MDA5 (201-300) positivi

Aurelie Najm AurelieRheumo

9 months 1 week ago
A new marker for stratification of ILD in dermatomyositis: Anti MDA5 antibodies! Japanese study MDA5 (201-300) positivity associated w/ Lower 6-month progression-free survival (43% vs. 74%) Lower 5-year survival rates (34% vs. 66%) Validation in other populations awaited https://t.co/IBiYyATer4
Dr. Werth on the #SLE guidelines on tx of cutaneous LE:
🔅All patients should be on hydroxychloroquine unless with CI

sheila RHEUMarampa

9 months 1 week ago
Dr. Werth on the #SLE guidelines on tx of cutaneous LE: 🔅All patients should be on hydroxychloroquine unless with CI. ☝️Important! For SLE pts presenting with new-onset rashes, review/ask about medications; consider drug-induced SCLE. #ACR25 @RheumNow https://t.co/ok5jAi7uO0
Getting down with Jack at the @RheumNow #ACR25 stand - come and say hello!

(and Ask Cush Anything - scan the QR code, a

David Liew drdavidliew

9 months 1 week ago
Getting down with Jack at the @RheumNow #ACR25 stand - come and say hello! (and Ask Cush Anything - scan the QR code, and maybe end up on the podcast!) https://t.co/0u0boHIIR3
#ACR25 In a rush and wondering which abstract to look out for pertaining to new update on Biologics in #SLE #lupus? Plea

Md Yuzaiful Md Yusof Yuz6Yusof

9 months 1 week ago
#ACR25 In a rush and wondering which abstract to look out for pertaining to new update on Biologics in #SLE #lupus? Please find my article on conference preview @RheumNow https://t.co/usIXPsj5bm https://t.co/4wmWvDyv83
Come to our first #HealthLiteracy poster of #ACR25!
#0190
Cluster analysis >900 people with IA
Lowest health literacy

Mrinalini Dey DrMiniDey

9 months 1 week ago
Come to our first #HealthLiteracy poster of #ACR25! #0190 Cluster analysis >900 people with IA Lowest health literacy cluster assoc w: 4× ⬆️anxiety/depression 2× ⬆️disease activity, vs highest HL Higher HL assoc w older age & ⬆️comorbidities but fewer mental health Sx @RheumNow https://t.co/iIRXaOl4qZ
How does cMRI change over time in cardiac EGPA?

Cheng et al. retrospectively reviewed:
- 11 EGPA pt with LGE on initia

Brian Jaros, MD Dr_Brian_MD

9 months 1 week ago
How does cMRI change over time in cardiac EGPA? Cheng et al. retrospectively reviewed: - 11 EGPA pt with LGE on initial cMRI Despite treatment: - 10/11 persistent LGE on 2nd cMRI - 4/4 on 3rd - 2/2 on 4th Unclear use as a monitor of tx response @RheumNow #ACR25
#0773 Anti-MDA5 epitope mapping identifies key regions (aa 201-300, 601-700) linked to treatment resistance & poor p

Mrinalini Dey DrMiniDey

9 months 1 week ago
#0773 Anti-MDA5 epitope mapping identifies key regions (aa 201-300, 601-700) linked to treatment resistance & poor prognosis in DM-ILD and even IIPs. Epitope-specific antibodies could refine risk stratification & guide therapy in ILD beyond autoimmune disease. @RheumNow #ACR25 https://t.co/moRffVGZPn
#ACR25 Abstr#0772. Should we be worried of #SLE patients with low uPCR 0.25-0.49? Kidney biopsy in N=28 + poor prognosti

Md Yuzaiful Md Yusof Yuz6Yusof

9 months 1 week ago
#ACR25 Abstr#0772. Should we be worried of #SLE patients with low uPCR 0.25-0.49? Kidney biopsy in N=28 + poor prognostic (Non-White, active serology or active sediment) - 71% had LN (No class IV or Mixed) - 46% actionable LN Cost-effectiveness data needed. #ACRBest @RheumNow https://t.co/Bt3fuA3aJh
Organ Specific Recommendations-ACR guidelines for Management of SLE by Dr Lisa Sammaritano. @RheumNow #ACR2025 https://t

Dr M Nazibur Rahman, MD (Rheumatology) NaziburM

9 months 1 week ago
Organ Specific Recommendations-ACR guidelines for Management of SLE by Dr Lisa Sammaritano. @RheumNow #ACR2025 https://t.co/ilKWG8CQbe
AI-enhanced MRI integrating STIR and T1-weighted MRI with BME data reflecting both inflammatory and structural changes,

Antoni Chan MD (Prof) synovialjoints

9 months 1 week ago
AI-enhanced MRI integrating STIR and T1-weighted MRI with BME data reflecting both inflammatory and structural changes, enabling the AI model to predict clinical diagnoses of axSpA with accuracy of 82%. Successfully identified axSpA patients who did not meet the ASAS criteria for https://t.co/dLlGj0ZFpj
Join us at 5pm CST for Day 1 #ACR25 recap! https://t.co/EwZSiPhysF

Dr. John Cush RheumNow

9 months 1 week ago
Join us at 5pm CST for Day 1 #ACR25 recap! https://t.co/EwZSiPhysF
The pharmacology treatment including biologics, cellular-based therapies, and Bi-specific T-cell Engager (BiTE) in systemic lupus erythematosus (SLE) is a rapidly expanding field of research that provides excitement and optimism to both the patients and the physicians.
×